Entries by Andrew Glover

Fsn1006: An antibody with dual specificity

Fsn1006 is a dual targeting antibody targeting both AREG (Amphiregulin) and HB-EGF (Heparin-binding EGF-like growth factor. The objective of this study was to humanize Fsn1006 while retaining the affinities.

Merry Christmas and Happy New Year

Merry Christmas and Happy New Year from Fusion! Fusion Antibodies would like to wish everyone a Merry Christmas and a Happy New year. Instead of sending out Christmas cards this year Fusion Antibodies have made a donation to Cancer Focus NI. Cancer focus is a fantastic Northern Irish charity which helps local people affected by cancer. […]

Fusion Antibodies develop new technologies with support of InvestNI

Invest NI has offered the company R&D support of £22,704 with an additional £46,600 offered to support a broad range of market development activities. Fusion Antibodies Ltd is helping to turn leading-edge research into novel drugs for the treatment of cancer and other chronic conditions with support from Invest Northern Ireland. With investment support form […]

Fusion Antibodies supports Movember

Fusion antibodies CTO Dr Richard Buick has pledged to raise awareness for men’s health issues and will grow a moustache throughout November. Fusion Antibodies Ltd has today announced a donation to support the worldwide Movember foundation. Fusion antibodies CTO Dr Richard Buick has pledged to raise awareness for men’s health issues and will grow a moustache throughout […]

Fusion Antibodies announce partnership with ISCA diagnostics

Fusion Antibodies CDRx platform has rapidly developed high quality humanized antibodies for Exeter based company Isca Diagnostics. The EU funded project will allow ISCA Diagnostics to provide the healthcare profession with easy access to rapid and accurate diagnostic tests for human mycoses. More details of the collaboration can be found on our recent press release […]

The CDRx Platform

Fusion Antibodies have developed a next generation computer platform for rapid, high quality generation of humanized antibodies. The CDRx platform modernizes the traditional CDR grafting technique by in silico grafting parental CDR’s into mature human antibody frameworks. The CDRx platform screens a database of over 100,000 antibody sequences with bespoke algorithms and, by multiple analytical techniques, defines […]

fsn0503 poster at Molecular Targets & Cancer Therapeutics conference

Our Fsn0503 poster will be displayed at this year’s International Conference on Molecular Targets and Cancer Therapeutics Our poster for “Fsn0503h antibody-mediated blockade of cathepsin S as potential therapeutic strategy for the treatment of solid tumors.” Will be displayed at: AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics http://www.aacr.org/home/scientists/meetings–workshops/molecular-targets-and-cancer-therapeutics.aspx October 19-23, 2013Hynes Convention CenterBoston, MA, […]

Fusion Antibodies announces collaboration with Calypso Biotech

Fusion Antibodies Ltd have today announced a collaboration with Swiss biotech company Calypso Biotech for development of their CALY-002 Antibody. Belfast UK and Geneva Switzerland – 22nd July 2013 – Fusion Antibodies Ltd have today announced a collaboration with Swiss biotech company Calypso Biotech for development of their CALY-002 Antibody. The humanization program CALY-002 partnered with […]